TELA BioTELA -4.54%54 Beneish M-Score is -3.51 as of Jun. 24, 2026. GuruFocus rates TELA with a GF Score™ of 54/100 and a GF Value™ of $1.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 765 Medical Devices & Instruments companies, TELA Bio ranks better than 89.02% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Good Sign:
Beneish M-Score -3.51 no higher than -1.78, which implies that the company is unlikely to be a manipulator.
The historical rank and industry rank for TELA Bio's Beneish M-Score or its related term are showing as below:
TELA'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.51 Med: -2.42 Max: -1.85
Current: -3.51
During the past 9 years, the highest Beneish M-Score of TELA Bio was -1.85. The lowest was -3.51. And the median was -2.42.
TELA Bio Beneish M-Score Related Terms
TELA Bio Beneish M-Score Historical Data
* Premium members only.
The historical data trend for TELA Bio's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TELA vs NSPR, PAVM, MYO: Beneish M-Score Comparison
For the Medical Devices subindustry, TELA Bio's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TELA Bio Beneish M-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where TELA Bio's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of TELA Bio for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.811
+
0.528 * 0.9952
+
0.404 * 0.6064
+
0.892 * 1.1348
+
0.115 * 0.9707
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.8888
+
4.679 * -0.14969
-
0.327 * 1.4091
=
-3.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(1.045 / (1.045 + 3.879))
/
(1.007 / (1.007 + 3.599))
=
0.212226
/
0.218628
=
0.9707
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-39.84 - 0.286
-
-29.664)
/
69.891
=
-0.14969
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
TELA Bio has a M-score of -3.51 suggests that the company is unlikely to be a manipulator.
TELA Bio (TELA) has a Beneish M-Score of -3.51 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TELA Bio and its competitors. According to the industry distribution chart, TELA Bio ranks #84 out of 765 companies in the Medical Devices & Instruments industry, placing it in the top 11%.
Is TELA Bio's Beneish M-Score too high?
TELA Bio's current Beneish M-Score is -3.51. Based on the distribution chart, TELA Bio ranks #84 out of 765 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, TELA Bio has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TELA Bio's Beneish M-Score compare to NSPR and PAVM?
According to the Medical Devices & Instruments industry distribution chart, TELA Bio ranks #84 out of 765 companies for Beneish M-Score. This places TELA Bio in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Medical Devices & Instruments company?
A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TELA Bio and its competitors. TELA Bio's current Beneish M-Score is -3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TELA Bio stock overvalued right now?
Based on GuruFocus' analysis, TELA Bio (TELA) is currently considered Possible Value Trap. The stock's GF Value™ is $1.67, compared to a current price of $0.75 — trading 55.1% below its estimated fair value. The current Beneish M-Score is -3.51. TELA Bio's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For TELA Bio (TELA), the current Beneish M-Score is -3.51 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TELA Bio (TELA) Overvalued in 2026?
Based on GuruFocus' analysis, TELA Bio stock appears to be undervalued.
The current stock price of $0.75 is trading 55.1% below its estimated GF Value™ of $1.67.
GuruFocus considers TELA Bio to be Possible Value Trap.
Key valuation signals for TELA:
Beneish M-Score: -3.51
GF Value™: $1.67 vs. price of $0.75 (55.1% below fair value)
No single metric tells the full story. See the TELA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
54GF Score
Get the complete analysis for TELA
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TELA has been successfully added to your 
